Join our daily newsletter At The Bell to receive exclusive market insights
- Actinogen Medical (ACW) enrols its first patient in Part A of a two-part trial targeting patients with mild cognitive impairment due to Alzheimer’s Disease
- The XanaMIA study determines the safety and efficacy of a 5 milligram and 10 milligram Xanamem dose on cognition over six weeks in 105 healthy volunteers
- The company says the results from Part A will confirm what dosage will be used for a Part B study on the use of Xanamem in patients with biomarker-positive Alzhiemer’s Disease
- Actinogen Medical last traded at 12 cents on July 14
Actinogen Medical (ACW) has enrolled its first patient in Part A of a two-part trial targeting patients with mild cognitive impairment due to Alzheimer’s Disease.
The study will determine the safety and efficacy of a 5 milligram and 10 milligram Xanamem dose on cognition over six weeks. Part A is being conducted across four outpatient sites in Australia and will see 105 healthy volunteers between the ages of 50 and 80 receiving dosages.
The enrolment follows ethics approval from the Bellberry Human Research Ethics Committee to begin the XanaMIA Part A study.
Previous studies by the company showed the use of Xanamem resulted in a statistically significant improvement in cognition over placebo in more than 200 healthy, older volunteers.
The Part A trial will use an iPad testing method with the sensitive endpoints of the Cogstate Neurological Test Battery, involving the Digit Symbol Substitution Test, which has been FDA approved for testing the ability to remember and think.
Actinogen CEO and MD Dr Steven Gourlay says the trial marks a significant milestone in the progression of Actinogen’s program to treat patients with Alzheimer’s Disease.
“This trial will add to the considerable safety and efficacy dataset the company has accumulated on Xanamem and will explore the minimally effective dose to be studied in future trials,” said Dr Steven Gourlay.
Actinogen says the results from Part A will confirm what dosage will be used for a Part B study, which will assess the efficacy of Xanamem in patients with biomarker-positive Alzhiemer’s Disease, indicative of the underlying disease processes in addition to those on cognition.
Actinogen Medical last traded at 12 cents on July 14.
